Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Gynaecology and Fertility

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 1 · 25%High 2 · 50%

Prevalence of dysmenorrhoea · women with symptomatic endometriosis

Mifepristone probably leads to lower prevalence of dysmenorrhoea compared with placebo (moderate certainty).

1 finding from 1 review

Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
OR 0.08 [0.04, 0.17]
1 study · 352 participants
Moderate

Prevalence of dyspareunia · women with symptomatic endometriosis

Mifepristone may leads to lower prevalence of dyspareunia compared with placebo (low certainty).

1 finding from 1 review

Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
OR 0.23 [0.1, 0.51]
1 study · 223 participants
Low

Side effects ‐ amenorrhoea · women with symptomatic endometriosis

Mifepristone leads to higher side effects: amenorrhoea compared with placebo (high certainty).

1 finding from 1 review

Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
OR 686.16 [92.29, 5101.33]
1 study · 360 participants
High

Side effects ‐ hot flushes · women with symptomatic endometriosis

Mifepristone leads to higher side effects: hot flushes compared with placebo (high certainty).

1 finding from 1 review

Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
OR 28.79 [3.93, 210.73]
1 study · 360 participants
High